TransMedics Group, Inc. is a medical technology company focused on the development and commercialization of organ care systems designed to improve the preservation and viability of donor organs for transplantation. The company’s core technology, the Organ Care System (OCS) platform, enables continuous perfusion of organs with oxygenated, nutrient-rich solutions under near-physiologic conditions. By maintaining organs in a functioning state outside the human body, TransMedics aims to extend preservation times, enhance organ assessment, and increase the pool of available donor organs.
The OCS platform currently encompasses systems tailored for lung, heart and kidney transplantation. The OCS Lung System, cleared by the U.S. Food and Drug Administration (FDA) and CE-marked in Europe, supports ex vivo lung perfusion to assess and rehabilitate marginal donor lungs. The OCS Heart System, which received FDA approval in 2021, employs normothermic perfusion to maintain the heart in a beating state, allowing transplant teams to evaluate cardiac function before implantation. TransMedics is also advancing its kidney perfusion technology, with clinical trials underway to demonstrate benefits in extending preservation times and improving post-transplant outcomes.
Headquartered in Andover, Massachusetts, TransMedics has established a growing presence across North America, Europe and select markets in Asia. The company collaborates with leading transplant centers and health authorities to integrate its perfusion technology into clinical practice. In addition to its proprietary hardware, TransMedics provides specialized disposables and perfusion solutions, training programs for surgical teams and ongoing technical support to promote the adoption of organ perfusion protocols worldwide.
Founded in 2005, TransMedics was co‐founded by physician-engineers committed to addressing critical gaps in organ transplantation. Today, Dr. Waleed Hassanein serves as President and Chief Executive Officer, guiding the company’s strategic vision for expanding indications and advancing clinical evidence. Under the leadership of CFO William Brennan and a seasoned executive team, TransMedics continues to invest in research and development, with the aim of transforming transplant medicine and improving patient outcomes.
AI Generated. May Contain Errors.
Free TMDX Stock Alerts